PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-09-16
Target enrollment:
Participant gender:
Summary
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation
and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic
and potential clinical benefit of PF-07265028 as a single agent and in combination with
sasanlimab, Anti-programmed cell death-1 (PD-1) monoclonal antibody, in participants with
advanced or metastatic solid tumors for whom no standard therapy is available.